In This Section:
Dr. Tim Beaumont
Dr. T Beaumont is the Managing Senior Scientist at AIMM Therapeutics, an Amsterdam based Biotech company focused on the discovery and development of therapeutic antibodies. Using the human B cell culture system developed by Dr. Beaumont, AIMM screens the immortalized B cell repertoire from human patients that have shown a strong immune response to an infection or disease. Dr. Beaumont and his team have discovered novel antibodies in such therapeutic areas as RSV, CMV, HCV, Influenza, MRSA, autoimmune disease, and certain cancers, with one antibody now in clinical trials and a second poised to enter the clinic later this year. Dr. Beaumont continues to advance the core technology in applications of in vitro affinity maturation and to non-human species. His current work follows-on his PhD and postdoctoral period where his research concentrated on adaptive and innate immune responses in HIV and SIV infection.